Tirzepatide use vs placebo was associated with slower decline in eGFR among patients with prediabetes and obesity or overweight.

Demand for glucagon-like peptide-1 weight-loss drugs — such as Ozempic, Zepbound and Wegovy — coupled with limited insurance coverage has fueled a risky but growing “gray” market for purchasing active ...

Tirzepatide was superior to semaglutide in achieving standard and intensive cardiometabolic targets among patients with type 2 diabetes.

Obesity has become a global epidemic, contributing to a host of chronic health conditions such as type 2 diabetes, ...

In a recent study published in Life Metabolism, researchers at Fudan University report that even after stopping the anti-obesity drug tirzepatide, ...

Explore the evolving US housing market: trends in homebuilder confidence, construction growth, renter vs. owner dynamics, and the impact of tariffs on costs.

ENDO 2025 Tirzepatide Outperforms Semaglutide on Combined T2D Goals Tirzepatide outperformed semaglutide in simultaneously achieving four key therapeutic targets for type 2 diabetes.